Based on sophisticated clinical descriptions and characteristic symptom patters occurring during the long-term course of psychiatric diseases, Leonhards classification requires that all the clinical features fit for a diagnosis to be made. Always using his own life-long case studies, Leonhard divided the endogenous psychoses into five main nosological groups: on the one hand, the prognostically favourable unipolar affective psychoses, bipolar affective psychoses and cycloid psychoses, and, on the other hand, the prognostically unfavourable unsystematic and systematic schizophrenia. In the meantime, the reliability and validity of this classification have been confirmed by scientific studies and early results provide guidelines for the different origins and varied therapeutic approaches for the specific disease profiles.
2013 sees the centenary of Jaspers' foundation of psychopathology as a science with the publication of his magnum opus the Allgemeine Psychopathologie (General Psychopathology), Many of the issues concerning methodology and diagnosis are today the subject of much discussion and debate. This volume brings together leading psychiatrists and philosophers to discuss the impact of this volume, its relevance today, and the legacy it left.
Today most of us accept the consensus that madness is a medical condition: an illness, which can be identified, classified and treated with drugs like any other. In this ground breaking and controversial work Richard Bentall shatters the myths that surround madness. He shows there is no reassuring dividing line between mental health and mental illness. Severe mental disorders can no longer be reduced to brain chemistry, but must be understood psychologically, as part of normal behaviour andhuman nature. Bentall argues that we need a radically new way of thinking about psychosis and its treatment. Could it be that it is a fear of madness, rather than the madness itself, that is our problem?
In order to accurately describe and diagnose psychiatric illness, practitioners require in-depth knowledge of the signs and symptoms of behavioral disorders. Descriptive Psychopathology provides a broad review of the psychopathology of psychiatric illness, beyond the limitations of the DSM and ICD criteria. Beginning with a discussion of the background to psychiatric classification, the authors explore the problems and limitations of current diagnostic systems. The following chapters then present the principles of psychiatric examination and diagnosis, described with accompanying patient vignettes and summary tables, and related to different diagnostic concerns. A thought-provoking conclusion proposes a restructuring of psychiatric classification based on the psychopathology literature and its validating data. Written for psychiatry and neurology residents, as well as clinical psychologists, it is invaluable to anyone who accepts the responsibility for the care of patients with behavioral syndromes.
Schizophrenia may not be a single disease, but the result of a diverse set of related conditions. Modern neuroscience is beginning to reveal some of the genetic and environmental underpinnings of schizophrenia; however, an approach less well travelled is to examine the medical disorders that produce symptoms resembling schizophrenia. This book is the first major attempt to bring together the diseases that produce what has been termed 'secondary schizophrenia'. International experts from diverse backgrounds ask the questions: does this medical disorder, or drug, or condition cause psychosis? If yes, does it resemble schizophrenia? What mechanisms form the basis of this relationship? What implications does this understanding have for aetiology and treatment? The answers are a feast for clinicians and researchers of psychosis and schizophrenia. They mark the next step in trying to meet the most important challenge to modern neuroscience – understanding and conquering this most mysterious of human diseases.
Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals. Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. - Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process - Critical evaluation of animal and translational models improving transition from drug discovery and clinical development - Emphasizes what results mean to the overall drug discovery process - Explores issues in clinical trial design and conductance in each therapeutic area - Each volume is available for purchase individually.
- The topics covered in the six sections of the book are Epidemiology and Environment, Precursors, Pathophysiological Mechanisms, Genetics, Controversies in Schizophrenia, and Treatment. - Reflects the progress made on Schizophrenia since 1986.
